Physician profile
Shuja Sheikh
NPI 1811383755
$4,578.41
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $364 · 2021: $1,125 · 2022: $1,761 · 2023: $1,294 · 2024: $33.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $624.69 | 2021-2023 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $274.07 | 2020-2023 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $250.57 | 2020-2023 | |
| Catalyst Pharmaceuticals, INC. | $193.20 | 2020-2023 | Firdapse |
| Teva Pharmaceuticals USA, INC. | $187.59 | 2020-2023 | Austedo Xr, Austedo |
| Lilly USA, LLC | $179.97 | 2021-2023 | Amyvid, Emgality |
| Livanova USA, INC. | $175.06 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Csl Behring | $172.62 | 2020-2024 | Hizentra |
| Alnylam Pharmaceuticals INC. | $164.32 | 2021-2023 | Onpattro, Amvuttra |
| Emd Serono, INC. | $148.89 | 2020-2023 | Mavenclad |
| Amgen INC. | $132.66 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $128.70 | 2020-2023 | Ultomiris |
| Jazz Pharmaceuticals INC. | $123.04 | 2022-2023 | Epidiolex |
| Takeda Pharmaceuticals U.S.A., INC. | $114.65 | 2021-2023 | Gammagard |
| Acorda Therapeutics, INC | $105.41 | 2020-2023 | Inbrija |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuja Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.